MacroGenics' Bonvini exercises options for 8,000 shares

The option schedule makes 12.5% of the grant exercisable after six months, followed by an additional 6.25% each three-month period.

Rhea-AI Filing Summary

MacroGenics' Sr VP, Research & CSO Ezio Bonvini exercised options to acquire and hold 8,000 shares of common stock on October 6, 2026, at a $2.60 per-share exercise price. After the transaction, he reported 193,799 shares of common stock and options covering 80,000 shares. The options expire February 7, 2035.

Insider Trade Summary

8,000 shares exercised/converted

Exercise 2 txns

Insider Bonvini Ezio

Role Sr VP, Research & CSO

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy) F2	8,000	$2.60	$21K
Exercise	Common Stock F1	8,000	$2.60	$21K

Holdings After Transaction: Employee Stock Option (right to buy) — 80,000 contracts (Direct); Common Stock — 193,799 shares (Direct)

Footnotes (2)

1. F1. The transaction represents an exercise and hold of options.
2. F2. 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

Key Figures

Common shares acquired: 8,000 shares Exercise price: $2.60 per share Common shares following transaction: 193,799 shares +2 more

5 metrics

Common shares acquired 8,000 shares October 6, 2026 option exercise

Exercise price $2.60 per share Options exercised on October 6, 2026

Common shares following transaction 193,799 shares Reported after the October 6, 2026 transaction

Shares underlying options following transaction 80,000 shares Reported after the October 6, 2026 transaction

Option expiration date February 7, 2035 Employee stock options

Key Terms

Employee Stock Option (right to buy), exercise and hold, exercisable

3 terms

Employee Stock Option (right to buy) financial

"Employee Stock Option (right to buy)"

exercise and hold financial

"represents an exercise and hold of options"

exercisable financial

"12.5% of the shares underlying the grant become exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MGNX shares did Ezio Bonvini acquire by exercising options?

Ezio Bonvini acquired 8,000 shares of common stock on October 6, 2026, at a $2.60 per-share exercise price; the transaction was reported as an exercise and hold of options.

What is the exercisability schedule for Ezio Bonvini's MGNX option grant?

12.5% of the shares underlying the grant become exercisable six months after the grant date, and an additional 6.25% become exercisable on the first day of each three-month period thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/07/2026 - 04:23 PM Accepted by SEC EDGAR 10/07/2026 - 04:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bonvini Ezio

(Last) (First) (Middle)

9704 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr VP, Research & CSO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/06/2026		M(1)		8,000	A	$2.6	193,799	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$2.6	10/06/2026		M			8,000	(2)	02/07/2035	Common Stock	8,000	$2.6	80,000	D

Explanation of Responses:

1. The transaction represents an exercise and hold of options.

2. 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

Remarks:

	/s/ Beth A. Smith, Attorney-in-fact	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)